Sign Up for a Free Account
  • Updated 01.26.2021
  • Released 12.07.1993
  • Expires For CME 01.26.2024

Botulism

Introduction

Overview

In this article, the author reviews the clinical manifestations, diagnostic tests, and management of patients who present with botulism: foodborne, wound, adult intestinal toxemia, iatrogenic (following medical or cosmetic administration), and inhalational botulism. Recent information on wound and foodborne botulism is presented, along with diagnostic evaluations and treatments. New antitoxin treatment recommendations are included.

Key points

• Botulinum toxin is one of the most potent neurotoxins in the world and is lethal in small doses.

• Botulinum toxin acts at the neuromuscular junction. It interferes with proteins involved in acetylcholine vesicle fusion at the presynaptic nerve terminal, thereby blocking release into cholinergic synapses of the peripheral nervous system.

• Most cases of foodborne botulism come from improperly home-canned foods whose preparation does not destroy C botulinum spores.

• Wound botulism occurs through skin infections, with an increased incidence in people who inject drugs.

• The definitive diagnosis of botulism is made by demonstrating the presence of botulinum toxin in serum, stool, or suspected food, or isolation of C botulinum from a wound, along with supportive clinical and electrodiagnostic features.

• Frequent monitoring of respiratory function is critical – either by forced vital capacity or negative inspiratory force; consider elective intubation for forced vital capacity less than 30% of predicted.

• Laboratory confirmation is done by demonstrating the presence of botulinum toxin in serum, stool, or food, or by culturing Clostridium species from stool or a wound.

•The Centers for Disease Control and Prevention (CDC) recommend administration of botulinum antitoxin as soon as the diagnosis is suspected.

Historical note and terminology

Botulism as a clinical entity was reported in 1897, when van Ermengem described the clinical, toxicological, and bacteriological features of an outbreak of foodborne botulism. He demonstrated that botulism was not due to an infection, but to an intoxication produced by a gram-positive, rod-shaped bacterium he named Bacillus botulinus, later called Clostridium botulinum. In the 1970s, Midura and Arnon identified infants developing paralysis following C botulinum colonization of the gastrointestinal tract, with subsequent release of botulinum toxin into the gut (58). Wound botulism was historically described in connection to traumatic injury. Its association with drug injection use was first reported in 1982 in New York City.

Before 1950, mortality from botulism was approximately 60% (25).

Although termed “botulinum neurotoxin” (BoNT), the toxin comes from 6 groups of bacteria: Clostridium botulinum I-IV, Clostridium baratii, and Clostridium butyricum (62). Botulinum toxin is a family of serologically related neurotoxins: types A, B, C1, D, E, F, G, and a variably classified H (28; 34).

Start a MedLink Neurology trial
to unlock 3 free articles.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com